Key facts for NCD 210.3
- Benefit category
- Colorectal Cancer Screening Tests
- Effective date
- 06/08/2026
- Implemented 01/04/2027
- Transmittal
- Transmittal 13921
- Versions published
- 8
TL;DR
NCD 210.3 sets Medicare's national policy for colorectal cancer screening tests under the benefit category "Colorectal Cancer Screening Tests", effective 06/08/2026 and implemented 01/04/2027. 1. Fecal Occult Blood Tests (FOBT) (effective January 1, 2004) It has been revised 7 times since publication and binds every Medicare Administrative Contractor nationally.
Item or service described
A. General
Sections 1861(s)(2)(R) and 1861(pp) of the Social Security Act (the Act) and regulations at 42 CFR 410.37 authorize Medicare coverage for screening colorectal cancer tests under Medicare Part B. The statute and regulations authorize the Secretary to add other tests and procedures (and modifications to tests and procedures for colorectal cancer screening) as the Secretary finds appropriate based on consultation with appropriate organizations.
Indications and limitations of coverage
B. Nationally Covered Indications
1. Fecal Occult Blood Tests (FOBT) (effective January 1, 2004)
Fecal occult blood tests (FOBTs) are generally divided into two types: immunoassay and guaiac types. Immunoassay (or immunochemical) fecal occult blood tests (iFOBT) use “antibodies directed against human globin epitopes. While most iFOBTs use spatulas to collect stool samples, some use a brush to collect toilet water surrounding the stool. Most iFOBTs require laboratory processing.
Guaiac fecal occult blood tests (gFOBT) use a peroxidase reaction to indicate presence of the heme portion of hemoglobin. Guaiac turns blue after oxidation by oxidants or peroxidases in the presence of an oxygen donor such as hydrogen peroxide. Most FOBTs use sticks to collect stool samples and may be developed in a physician’s office or a laboratory. In 1998, Medicare began reimbursement for guaiac FOBTs, but not immunoassay type tests for colorectal cancer screening. Since the fundamental process is similar for other iFOBTs, the Centers for Medicare & Medicaid Services evaluated colorectal cancer screening using immunoassay FOBTs in general.
Medicare covers one screening FOBT per annum for the early detection of colorectal cancer. This means that Medicare will cover one gFOBT or one iFOBT at a frequency of every 12 months; i.e., at least 11 months have passed following the month in which the last covered screening FOBT was performed, for beneficiaries aged 45 years and older. The beneficiary completes the existing gFOBT by taking samples from two different sites of three consecutive stools; the beneficiary completes the iFOBT by taking the appropriate number of stool samples according to the specific manufacturer’s instructions. This screening requires a written order from the beneficiary’s attending physician (“Attending physician” means a doctor of medicine or osteopathy (as defined in §1861(r)(1) of the Act), physician assistant, nurse practitioner, or clinical nurse specialist who is fully knowledgeable about the beneficiary’s medical condition, and who would be responsible for using the results of any examination performed in the overall management of the beneficiary’s specific medical problem.)
The minimum age for FOBT is reduced to 45 years and older.
2. Non-Invasive Biomarker Tests
Biomarker testing detects molecular markers shed by colorectal cancer and pre- malignant colorectal epithelial neoplasia into blood, bodily secretions, or directly into the intestinal lumen. Through the use of selective enrichment and amplification techniques, tests are designed to detect very small amounts of markers to identify colorectal cancer or pre-malignant colorectal neoplasia.
Non-Invasive Biomarker tests are covered once every 3 years under the following conditions:
• Ordering Criteria
• When ordered by the physician, physician assistant, nurse practitioner, or clinical nurse specialist who will use the results in the management of the patient.
• Patient Criteria
• Age 45 to 85 years; and,
• Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive non-invasive biomarker colorectal cancer screening test); and,
• At average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn’s Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer); and,
• Provided with information about the test performance and the importance of a follow-on colonoscopy if the test returns a positive result.
• Test Criteria
• The test must be Food and Drug Administration (FDA) market authorized and indicated for colorectal cancer screening; and,
• The test must achieve the requirements of the FDA-required post-approval study as specified in the Safety and Effectiveness Data (SSED) to continue coverage ; and
• The test must be processed in a CLIA certified laboratory; and,
• The test must demonstrate performance characteristics that meet EITHER Criteria 1 , a sensitivity of greater than or equal to 90% and a specificity greater than or equal to 87%, OR Criteria 2 , a sensitivity of greater than or equal to 79% and a specificity of greater than or equal to 90% in the detection of colorectal cancer compared to the recognized standard (accepted as colonoscopy at this time), based on the FDA labeling.
Test Performance
Criteria 1
Test Performance
Criteria 2
Sensitivity for CRC
≥ 90%
≥ 79%
Specificity for CRC
≥ 87%
≥ 90%
C. Nationally Non-Covered Indications
All other indications for colorectal cancer screening not otherwise specified in the Act and regulations, or otherwise specified above remain nationally non-covered.
D. Other
(This NCD was last reviewed June 2026 and includes updates finalized in the Calendar Year 2025 Physician Fee Schedule final rule 89 FR 97710)
Text reproduced from the CMS Medicare Coverage Database record for NCD 210.3 version 8. View the original on cms.gov.
Local policies that build on this NCD
11 active Local Coverage Determinations cite NCD 210.3 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- Diagnostic and Therapeutic Colonoscopy (L34213) · Noridian Healthcare Solutions, LLC
- LCD L35396: Biomarkers for Oncology · Novitas Solutions, Inc.
- Colon Capsule Endoscopy (CCE), LCD L38805 · First Coast Service Options, Inc.
- Genetic Testing in Oncology: Specific Tests (L39365) · Novitas Solutions, Inc.
- L38571 Colon Capsule Endoscopy (CCE) · Wellpoint Federal
- L38755 Colon Capsule Endoscopy (CCE) · Palmetto GBA
- L38777 Colon Capsule Endoscopy (CCE) · CGS Administrators, LLC
- L38807 Colon Capsule Endoscopy (CCE) · Novitas Solutions, Inc.
- L38824 Colon Capsule Endoscopy (CCE) · Noridian Healthcare Solutions, LLC
- L38837 Colon Capsule Endoscopy (CCE) · Wisconsin Physicians Service Insurance Corporation
- L39367 Genetic Testing in Oncology: Specific Tests · First Coast Service Options, Inc.
How MACs bill NCD 210.3
A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 3 current articles in the Medicare Coverage Database name NCD 210.3, 3 of them with a covered ICD-10-CM list, from 2 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.
| Contractor | Articles |
|---|---|
| Noridian Healthcare Solutions, LLC | A57342, A58436 |
| Wellpoint Federal | A58294 |
A57342: Billing and Coding: Diagnostic and Therapeutic Colonoscopy
Billing and Coding, effective 2025-11-06 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record
273 covered ICD-10-CM codes; 26 procedure codes: 44388, 44389, 44390, 44391, 44392, 44394, 44401, 44402, 44404, 44405, 44406, 44407 and 14 more. Local policy: L34213 Diagnostic and Therapeutic Colonoscopy. Check a diagnosis for 44388.
First covered codes: A04.3 Enterohemorrhagic Escherichia coli infection; A04.5 Campylobacter enteritis; A04.71 Enterocolitis due to Clostridium difficile, recurrent; A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent; A06.0 Acute amebic dysentery; A06.1 Chronic intestinal amebiasis; …
A58294: Billing and Coding: Colon Capsule Endoscopy (CCE)
Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record
6 covered ICD-10-CM codes; 1 procedure code: 91113. Local policy: L38571 Colon Capsule Endoscopy (CCE). Check a diagnosis for 91113.
First covered codes: K63.5 Polyp of colon; K92.1 Melena; K92.2 Gastrointestinal hemorrhage, unspecified; R19.5 Other fecal abnormalities; Z53.09 Procedure and treatment not carried out because of other contraindication; Z53.8 Procedure and treatment not carried out for other reasons.
A58436: Billing and Coding: Colon Capsule Endoscopy (CCE)
Billing and Coding, effective 2025-09-11 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record
6 covered ICD-10-CM codes; 1 procedure code: 91113. Local policy: L38824 Colon Capsule Endoscopy (CCE). Check a diagnosis for 91113.
First covered codes: K63.5 Polyp of colon; K92.1 Melena; K92.2 Gastrointestinal hemorrhage, unspecified; R19.5 Other fecal abnormalities; Z53.09 Procedure and treatment not carried out because of other contraindication; Z53.8 Procedure and treatment not carried out for other reasons.
Coverage analysis history
CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 5 analyses to NCD 210.3, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.
- CAG-00180N Screening Immunoassay Fecal-Occult Blood Test (New, Closed)
- CAG-00144N Screening DNA Stool Test for Colorectal Cancer (New, Closed)
- CAG-00440N Screening for Colorectal Cancer - Stool DNA Testing (New, Closed)
- CAG-00454N Screening for Colorectal Cancer - Blood-Based Biomarker Tests (New, Closed)
- CAG-00440R Screening for Colorectal Cancer-Non-Invasive Biomarker Tests (1st Recon, Closed)
Revision history
08/2026 - The purpose of this Change Request (CR) is to inform contractors that CMS has determined that effective June 8, 2026, non-invasive biomarker screening tests are appropriate colorectal cancer screening tests based on specific criteria. ( TN 13921 ) (CR14581)
09/2025 - Transmittal 13400 issued September 05, 2025, is being rescinded and replaced by Transmittal 13438, dated September 30, 2025, to add a new attachment to ensure the functionality of the NCD zip URL is working properly and to update the Policy section. All other information remains the same.
The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 coding changes specific to NCDs. ( TN 13438 ) (CR14197)
08/2025 - The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 coding changes specific to NCDs. ( TN 13375 ) (CR14197)
03/2025 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 13097 ) (CR13939)
10/2024 - The purpose of the Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations(NCDs). No policy is being changed as a result of these updates. ( TN 12904 ) (CR13828)
01/2024 - Transmittal 12350 issued November 03, 2023, is being rescinded and replaced by Transmittal 12440 dated January 3, 2024, to make changes to NCD 90.2, Next Generation Sequencing, spreadsheet to align with revisions being made to CR 13278. All other information remains the same. ( TN 12440 ) (CR13391)
11/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates.( TN 12350 ) (CR13391)
10/2023 - The purpose of this Change Request (CR) is to provide a quarterly maintenance update of ICD-10 coding conversions and other coding updates specific to National Coverage Determinations (NCDs). No policy is being changed as a result of these updates. ( TN 12319 ) (CR13391)
02/2023 - Transmittal 11824 issued January 27, 2023, is being rescinded and replaced by Transmittal 11865, dated, February 16, 2023, to add the Spanish version of MSN Message 18.29 to the IOM for publication 100-04. This correction does not make any revisions to the companion Pubs.100-02 or 100-03; all revisions are associated with Pub. 100-04. All other information remains the same. ( TN 11865 ) (CR13017)
01/2023 - The purpose of this omnibus Change Request (CR) is to make contractors aware of policy updates resulting from changes specified in the Calendar Year (CY) 2023 Physician Fee Schedule (PFS) Final Rule (87 FR 69404), published in the Federal Register on 11/18/2022. The policy updates include removal of one selected National Coverage Determination (NCD) : Ambulatory Electroencephalographic (EEG) Monitoring (NCD 160.22). Separately, the policy updates also include policies to expand colorectal cancer screening coverage by 1) reducing the minimum age for certain CRC screening tests from 50 to 45 years and 2) expanding the regulatory definition of CRC screening tests to include a follow-on screening colonoscopy after a Medicare covered non-invasive stool-based test returns a positive result. ( TN 11824 ) (CR13017)
05/2021 - The purpose of this Change Request (CR) is to inform contractors that CMS has determined effective on January 19, 2021 blood-based biomarker test is an appropriate colorectal cancer screening test based on specific criteria.The Federal government creates NCDs that are binding on the MACs who review and/or adjudicate claims, make coverage determinations, and/or payment decisions, and also binds quality improvement organizations, qualified independent contractors, the Medicare appeals council, and Administrative Law Judges (ALJs) (see 42 Code of Federal Regulations (CFR) section 405.1060(a)(4) (2005)). An NCD that expands coverage is also binding on a Medicare advantage organization. In addition, an ALJ may not review an NCD. (See section 1869(f)(1)(A)(i) of the Social Security Act.) ( TN 10818 ) (CR12280)
02/2020 - This Change Request (CR) constitutes a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.
Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 2427 ) (CR11491)
02/2018 - Transmittal 2033, dated February 16, 2018, is being rescinded and replaced by Transmittal 2039, dated, February 28, 2018 to correct instructions in business requirement 7, NCD210.3, Colorectal Cancer Screening, and its accompanying spreadsheet. All other information remains the same. ( TN 2039 ) (CR10473)
02/2018 - This Change Request (CR) constitutes a maintenance update of International Code of Diseases, Tenth Revision (ICD-10) conversions and other coding updates specific to National Coverage Determinations (NCDs). These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.
Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 2033 ) (CR10473)
02/2017 - This change request (CR) is the 10th maintenance update of ICD-10 conversions and other coding updates specific to national coverage determinations (NCDs). These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.
Previous NCD coding changes appear in ICD-10 quarterly updates as follows: CR7818, CR8109, CR8197, CR8691, CR9087, CR9252, CR9540, CR9631, and CR9751, as well as in CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent, quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 1792 ) (CR9861)
06/2016 - Transmittal 1665, dated May 13, 2016, is being rescinded and replaced by Transmittal 1672 to: (1) 9631.1: Remove FISS responsibility and 1st sentence; (2) 9631.2: Remove additional procedure codes, including 0075T, 0076T; (3) 9631.4: Revise descriptor of dx L59.8; (4) 9631.6: Add deletion of dx C49.10, C65.9, remove deletion of dx C54.9, remove deletion of invalid dx C47.90; (5) 9631.8: Remove deletion of invalid dx C51.29, replace with deletion of dx C50.029; (6) 9631.9: Add deletion of 0V504ZZ, 0V500ZZ, override capability, and contractor discretion verbiage. All other information remains the same. ( TN 1672 ) (CR9631)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 210.3
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 210.3
What does NCD 210.3 cover?
1. Fecal Occult Blood Tests (FOBT) (effective January 1, 2004) The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 210.3 take effect?
The current version (8) is effective 06/08/2026, implemented 01/04/2027, published in transmittal 13921. CMS lists 8 versions of this NCD.
Does a Local Coverage Determination override NCD 210.3?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- Medicare Coverage Database national coverage analyses (NCA/CAL report) via the CMS Coverage APIVersion API snapshot 2026-11-16 · effective 2026-11-16 · file national-coverage-ncacal.jsonSHA-256 563369a07b95140a…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.